Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Posts 2-Percent Increase in LSCA Revenues; Confirms Plans to Sell Chip Business

Click here to read an updated version of this article.

NEW YORK, Aug. 15 (GenomeWeb News) - Agilent Technologies today reported a 2-percent increase in revenues for its Life Science and Chemical Analysis unit and a 7-percent decline in profit for the segment for its third fiscal quarter, ended July 31.

 

Separately, Agilent said that it plans to sell its semiconductor business for $2.66 billion to Kohlberg Kravis Roberts & Co. and Silver Lake Partners in a deal expected to close by Oct. 31. Agilent will lay off around 1,300 employees as part of a restructuring plan related to the divestiture, which the company said will enable it to focus on its measurement business.

 

Agilent's total revenues fell 10 percent to $1.69 billion for the quarter from $1.89 billion in the prior-year period. Revenues fell below the company's expectations of $1.7 billion to $1.8 billion for the quarter. "Revenues were slightly below our expectations because of weak wireless test and life sciences markets," said Bill Sullivan, Agilent CEO, in a statement.

 

The LSCA unit posted receipts of $341 million for the quarter, a slight increase over $335 million in the year-ago period. Orders for the unit increased 8 percent, to $348 million from $321 million in the prior year.

 

Operating profit for the LSCA unit fell to $42 million, compared to $45 million in the equivalent period of 2004. Excluding the impact of recent acquisitions, profits for the LSCA group were flat year over year, the company said.

 

Agilent noted that it witnessed "particular strength" in the life science group from generic drug manufacturers, but "some weakness in near-term pharmaceutical demand."

 

Agilent posted net earnings of $104 million, or $.21 per share, compared to $100 million, or $.20 per share in last year's third fiscal quarter.

 

Quarterly R&D expenses increased 5 percent to $244 million from $235 million in the year-ago period.

 

Agilent had cash and cash equivalents of $2.8 billion as of July 31.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.